GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
53.32
+0.23 (0.43%)
At close: Jul 7, 2026, 4:00 PM EDT
53.00
-0.32 (-0.60%)
After-hours: Jul 7, 2026, 7:13 PM EDT
GSK plc Employees
GSK plc had 66,841 employees as of December 31, 2025. The number of employees decreased by 1,788 or -2.61% compared to the previous year.
Employees
66,841
Change (1Y)
-1,788
Growth (1Y)
-2.61%
Revenue / Employee
$647,583
Profits / Employee
$115,154
Market Cap
106.77B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 66,841 | -1,788 | -2.61% |
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
| Dec 31, 2019 | 99,437 | 3,947 | 4.13% |
| Dec 31, 2018 | 95,490 | -2,972 | -3.02% |
| Dec 31, 2017 | 98,462 | -838 | -0.84% |
| Dec 31, 2016 | 99,300 | -1,955 | -1.93% |
| Dec 31, 2015 | 101,255 | 3,334 | 3.40% |
| Dec 31, 2014 | 97,921 | -1,530 | -1.54% |
| Dec 31, 2013 | 99,451 | -37 | -0.04% |
| Dec 31, 2012 | 99,488 | 2,099 | 2.16% |
| Dec 31, 2011 | 97,389 | 928 | 0.96% |
| Dec 31, 2010 | 96,461 | -3,452 | -3.46% |
| Dec 31, 2009 | 99,913 | 910 | 0.92% |
| Dec 31, 2008 | 99,003 | -4,480 | -4.33% |
| Dec 31, 2007 | 103,483 | 788 | 0.77% |
| Dec 31, 2006 | 102,695 | 1,967 | 1.95% |
| Dec 31, 2005 | 100,728 | 709 | 0.71% |
| Dec 31, 2004 | 100,019 | -900 | -0.89% |
| Dec 31, 2003 | 100,919 | -3,580 | -3.43% |
| Dec 31, 2002 | 104,499 | -2,971 | -2.76% |
| Dec 31, 2001 | 107,470 | -47 | -0.04% |
| Dec 31, 2000 | 107,517 | -1,524 | -1.40% |
| Dec 31, 1999 | 109,041 | -7,780 | -6.66% |
| Dec 31, 1998 | 116,821 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| AbbVie | 57,000 |
| Bristol-Myers Squibb Company | 32,500 |
GSK News
- 2 hours ago - Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs - Reuters
- 1 day ago - GSK upgraded to Hold from Reduce at HSBC - TheFly
- 5 days ago - A Look at GSK PLC (GSK) After 4.6% Gain -- GF Value $43.94 vs Price $53.66 - GuruFocus
- 5 days ago - GSK (GSK) Has a Vaccines-and-Specialty-Medicines Mix Bigger Than a Patent-Expiry Debate - AlphaStreet
- 13 days ago - GSK Initiates Tender Offer for Nuvalent Shares - GuruFocus
- 13 days ago - GSK announces commencement of tender offer to acquire Nuvalent - TheFly
- 20 days ago - Spero: FDA Approves Utebzi, The First Oral Carbapenem For Complicated UTIs In Adults; Stock Up - Nasdaq
- 20 days ago - Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) - Business Wire